MedTech Company BioSig Technologies Deploys Disruptive Technology To Improve Arrhythmia Care

MedTech, HealthTech, Benzinga, BioSig Technologies, BioPharmaceuticals, Jessica Abraham, Jessica N Abraham,

This article was previously published to Benzinga. Arrhythmia is a heart condition that causes it to beat either too fast, or irregularly. It’s triggered by abnormal electrical activity and affects the heart’s rhythm, leading it to beat out of sync with the rest of the body.  Not every patient experiences arrhythmia in the same way, so it’s sometimes necessary for doctors to provide each patient with a personalized approach to treatment and recovery.  Lifestyle choices and comorbidities, […]

Continue Reading

Groundbreaking Studies to Be Conducted on the Effectiveness of Short and Long-term COVID-19 Therapies Inhibiting the Progression of SARS-CoV-2

Statera Pharmaceuticals treatment for Covid-19 Long-Haulers

Previously Published to Benzinga: The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Statera Biopharma, Inc. (NASDAQ: STAB) recently announced that it has officially received Institutional Review Board (IRB) approval to conduct a Phase 1 pilot study at Loma Linda University Health to evaluate STAT-205 as a treatment in the mitigation of SARS-CoV-2 progression. STAT-205 is a breakthrough immuno-modulator designed to decrease elevated […]

Continue Reading

What is ImQuest, and How is Statera Biopharma using it to Develop New Immune Therapies for Cancer, Infectious Disease and Autoimmune Disorders?

What is ImQuest, and How is Statera Biopharma using it to Develop New Immune Therapies for Cancer, Infectious Disease and Autoimmune Disorders?

Previously Published to Benzinga: The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Statera Biopharma, Inc. (NASDAQ: STAB) — the company formerly known as Cytocom (NASDAQ: CBLI) — recently uplisted to the Nasdaq in lieu of earlier acquisitions involving Cleveland BioLabs and ImQuest Life Sciences, Inc. Last week, the company provided an update on its integration of ImQuest and its plans going forward.  According to Statera, preclinical testing is underway in the […]

Continue Reading

Statera BioPharma: The Ticker Formerly Known as CBLI

Statera Biopharmaceuticals, Groundbreaking Biomedicine Treatment

Previously Published to Benzinga: The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. On September 1, 2021, Cytocom officially became listed as Statera BioPharma, Inc. (NASDAQ: STAB), as it updated its ticker symbol from CLBI to STAB within the Nasdaq markets.  This change in name comes as a natural progression, as the company shifts gears toward placing a more strategic focus on restoring total […]

Continue Reading

Age-Related Macular Degeneration: What is Dry AMD, and How is Lineage Cell Therapeutics Changing the Game?

Age-Related Macular Degeneration DRY AMD, Lineage Cell Therapeutics

Previously Published to Benzinga: The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Age-related macular degeneration (AMD) is a disease originating in the retina, which may worsen over time, according to WebMD. It’s said to be the leading cause of severe, permanent vision loss in people older than 60.  When the macula — the small central portion of the retina — wears down, […]

Continue Reading